Top

Published in:

01-05-2009 | Original Article—Liver, Pancreas, and Biliary Tract

Type 1 autoimmune hepatitis and adipokines: new markers for activity and disease progression?

Authors: Marilena Durazzo, Grazia Niro, Alberto Premoli, Enrico Morello, Erik Rosa Rizzotto, Roberto Gambino, Simona Bo, Giovanni Musso, Maurizio Cassader, Gianfranco Pagano, Annarosa Floreani

Published in: Journal of Gastroenterology | Issue 5/2009

Abstract

Purpose

Cytokines may play an important role as inflammatory factors in liver diseases. There is some evidence suggesting a link between adiponectin–biliary function and liver disease. The aim of this study was to clarify the behavior of adipokines in autoimmune hepatitis type 1.

Methods

We assessed the circulating levels of adiponectin, tumor necrosis factor-α, resistin and leptin in 42 patients with autoimmune hepatitis, comparing them with 42 healthy subjects who were matched for age and sex and with 31 patients with nonalcoholic steatohepatitis (NASH), evaluating the associations with markers of cytolysis, cholestasis, and histological severity.

Results

Adiponectin and TNF-α values were higher in patients compared to controls. The patients showed significantly higher Homeostasis Model Assessment values, suggesting an increased insulin resistance and serum levels of adiponectin positively correlated with γ-glutamyltranspeptidase and alkaline phosphatase values after a simple regression analysis. Serum levels of resistin positively correlated with elevated aminotransferases and bilirubin values, and serum levels of TNF-α positively correlated with elevated alanine-aminotransferase and resistin values. The concentration of adiponectin increased significantly with staging of the disease. Patients with NASH showed lower levels of adiponectin and higher levels of resistin than AIH patients and controls.

Conclusions

Patients with AIH showed significantly higher adiponectin concentrations than controls despite their higher HOMA-IR values. The significant correlation between adiponectin levels and serological features of cholestasis suggested an association with biliary function. Our results indicate that adiponectin may be a possible marker for disease progression in AIH.

Floreani A, Niro G, Rosa Rizzotto E, Antoniazzi S, Ferrara F, Carderi I, et al. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther. 2006;24:1051–7.PubMedCrossRef

Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia. 2003;46:1594–603.PubMedCrossRef

Muto Y, Nouri-Aria KT, Meager A, Alexander GJ, Eddleston AL, Williams R. Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet. 1988;2:72–4.PubMedCrossRef

Zylberberg H, Rimaniol AC, Pol S, Masson A, De Groote D, Berthelot P, et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol. 1999;30:185–9.PubMedCrossRef

Vergani D, Mieli-Vergani G. Autoimmune hepatitis. Autoimmun Rev. 2003;2:241–7.PubMedCrossRef

Friedman JM. Leptin, leptin receptors and the control of body weight. Eur J Med Res. 1997;2(1):7–13.PubMed

McGillis JP. White adipose tissue, inert no more!. Endocrinology. 2005;146:2154–6.PubMedCrossRef

Martin-Romero C, Santos-Alvarez J, Goberna R, Sanchez-margalet V. Human leptin enhances activation and proliferation of human circulating T lymphocytes. Cell Immunol. 2000;199:15–24.PubMedCrossRef

Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology. 2002;122:1399–410.PubMedCrossRef

10.

Ikejima K, Honda H, Yoshikawa M, Hirose M, Kitamura T, Takei Y, et al. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology. 2001;34:288–97.PubMedCrossRef

11.

Manolakopoulos S, Bethanis S, Liapi C, Stripeli F, Sklavos P, Margeli A, et al. An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study. BMC Gastroenterol. 2007;7:17.PubMedCrossRef

12.

Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005;174:5789–95.PubMed

13.

Hanley AJ, Bowden D, Wagenknecht LE, Balasubramanyam A, Langfeld C, Saad MF, et al. Associations of adiponectin with body fat distribution and insulin sensitivity in non-diabetic Hispanic and African Americans. J Clin Endocrinol Metab. 2007;92:2665–71.PubMedCrossRef

14.

Cheng KK, Lam KS, Wang Y, Yu H, Carling D, Wu D, et al. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes. 2007;56:1387–94.PubMedCrossRef

15.

Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007;380:24–30.PubMedCrossRef

16.

Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation. 2007;115:1408–16.PubMedCrossRef

17.

Musso G, Gambino R, Biroli G, Carello M, Fagà E, Pacini G, et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2005;100:2438–46.PubMedCrossRef

18.

Musso G, Gambino R, Durazzo M, Biroli G, Carello M, Fagà E, et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology. 2005;42:1175–83.PubMedCrossRef

19.

Targher G, Bertolini L, Rodella S, Zoppini G, Scala L, Zenari L, et al. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol. 2006;64:679–83.CrossRef

20.

Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun. 2004;323:630–5.PubMedCrossRef

21.

Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver disease. Am J Gastroenterol. 2006;101:2629–40.PubMed

22.

Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–38.PubMedCrossRef

23.

Bo S, Gentile L, Ciccone G, Baldi C, Benini L, Dusio F, et al. The metabolic syndrome and high C-reactive protein: prevalence and difference by sex in a southern-european population-based cohort. Diabetes Metab Res Rev. 2005;21:515–24.PubMedCrossRef

24.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.PubMedCrossRef

25.

Kakizaki S, Sohara N, Yamazaki Y, Horiguchi N, Kanda D, Kabeya K, et al. Elevated plasma resistin concentrations in patients with liver cirrhosis. J Gastroenterol Hepatol. 2008;23(1):73–7.PubMedCrossRef

26.

Petrides AS. Liver disease and diabetes mellitus. Diabetes Rev. 1994;2:2–18.

27.

Jonsson JR, Moschen AR, Hickman IJ, Richardson MM, Kaser S, Clouston AD, et al. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol. 2005;43:929–36.PubMedCrossRef

28.

Tietge UJ, Boker KH, Manns MP, Bahr MJ. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab. 2004;287:E82–9.PubMedCrossRef

29.

Kaser S, Moschen A, Kaser A, Ludwiczek O, Ebenbichler CF, Vogel W, et al. Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J Intern Med. 2005;258:274–80.PubMedCrossRef

30.

Sohara N, Takagi H, Kakizaki S, Sato K, Mori M. Elevated plasma adiponectin concentrations in patients with liver cirrhosis correlate with plasma insulin levels. Liver Int. 2005;25:28–32.PubMedCrossRef

31.

Tacke F, Wustefeld T, Horn R, Luedde T, Srinivas Rao A, Manns MP, et al. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol. 2005;42:666–73.PubMedCrossRef

32.

Floreani A, Variola A, Niro G, Premoli A, Baldo V, Gambino R, et al. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. Am J Gastroenterol. 2008;103:1–7.CrossRef

33.

Zoccali C, Mallamaci F, Panuccio V, Tripepi G, Cutrupi S, Parlongo S, et al. Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int Suppl. 2003;84:S98–102.PubMedCrossRef

34.

Hui CK, Zhang HY, Lee NP, Chan W, Yueng YH, Leung KW, et al. Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B. J Hepatol. 2007;47:191–202.PubMedCrossRef

35.

Siagris D, Vafiadis G, Michalaki M, Lekkou A, Starakis I, Makri M, et al. Serum adiponectin in chronic hepatitis C and B. J Viral Hep. 2007;14:577–83.CrossRef

36.

Tsochatzis E, Papatheodoridis GV, Hadziyannis E, Georgiou A, Kafiri G, Tiniakos DG, et al. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol. 2008;30:1–9.

Title: Type 1 autoimmune hepatitis and adipokines: new markers for activity and disease progression?
Authors: Marilena Durazzo
Grazia Niro
Alberto Premoli
Enrico Morello
Erik Rosa Rizzotto
Roberto Gambino
Simona Bo
Giovanni Musso
Maurizio Cassader
Gianfranco Pagano
Annarosa Floreani
Publication date: 01-05-2009
Publisher: Springer Japan
Published in: Journal of Gastroenterology / Issue 5/2009
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI: https://doi.org/10.1007/s00535-009-0023-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2009

Interstitial cells of Cajal do not harbor c-kit or PDGFRA gene mutations in patients with sporadic gastrointestinal stromal tumors

Gastric emptying of liquid and solid meals at various temperatures

Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis

Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

Utility of the new Japanese severity score and indications for special therapies in acute pancreatitis

The effect and mechanism of action of capsaicin on gastric acid output

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials